<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Teva Pharmaceutical Industries</title>
	<atom:link href="http://www.stockbloghub.com/tag/teva-pharmaceutical-industries/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(TEVA) Teva Pharmaceuticals&#8217; Copaxone Challenged</title>
		<link>http://www.stockbloghub.com/2009/09/16/teva-teva-pharmaceuticals-copaxone-challenged/15391</link>
		<comments>http://www.stockbloghub.com/2009/09/16/teva-teva-pharmaceuticals-copaxone-challenged/15391#comments</comments>
		<pubDate>Wed, 16 Sep 2009 22:14:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15391</guid>
		<description><![CDATA[Shares of generic player Teva Pharmaceuticals, Inc. (TEVA) were down approximately 2% on news regarding the acceptance of an abbreviated new drug application (ANDA) for its multiple sclerosis drug, Copaxone. The ANDA, filed by generic company Mylan, Inc. (MYL) was accepted for review on September 14, 2009. The filing and acceptance of Mylan’s ANDA does not come as a surprise. Last year, Mylan had declared its plans to sell a generic version of Copaxone and had entered into a license and supply agreement with Indian company, NATCO Pharma Ltd., for exclusive distribution rights to pre-filled syringes of Copaxone in the U.S. and all major markets in Europe, Australia, New Zealand, Japan and Canada. We note that Teva is already facing a generic challenge for Copaxone from Momenta Pharmaceutical and Novartis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/teva-teva-pharmaceuticals-copaxone-challenged/15391/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme&#8217;s Multiple Sclerosis Drug Shows Promise</title>
		<link>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277</link>
		<comments>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:27:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15277</guid>
		<description><![CDATA[On Friday, Genzyme Corp. (GENZ) presented encouraging four-year follow-up phase II data on alemtuzumab, which is being developed for the treatment of multiple sclerosis (MS). Results showed durable reductions in relapse rate and sustained accumulation of disability even three years after patients received their last course of alemtuzumab. The company presented these efficacy and safety data at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis in Germany. This CAMMS223 study was conducted in early, relapsing-remitting MS patients, who were randomized to receive either alemtuzumab or Pfizer/Serono&#8217;s (PFE) Rebif. Patients taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 72% and the risk of sustained accumulation of disability by 73% compared to patients receiving Rebif. Additionally, the annualized relapse rate and disability risk ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

